Five‐year efficacy and safety of tafasitamab in patients with relapsed or refractory DLBCL: Final results from the Phase II L‐MIND study.

Autor:	Duell, J., Abrisqueta, P., Andre, M., Augustin, M., Gaidano, G., Barca, E. G., Jurczak, W., Kalakonda, N., Liberati, A. M., Maddocks, K. J., Menne, T., Nagy, Z., Tournilhac, O., Bakuli, A., Amin, A., Gurbanov, K., Salles, G.
Předmět:	DIFFUSE large B-cell lymphomas PATIENT safety ANTIBODY-dependent cell cytotoxicity CURATIVE medicine
Zdroj:	Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p437-439, 3p
Abstrakt:	Encore Abstract - previously submitted to AACR 2023 The research was funded by: MorphoSys AG Keyword: Aggressive B-cell non-Hodgkin lymphoma B Conflicts of interests pertinent to the abstract. b B J. Duell b Research funding: MorphoSys AG, Regeneron B P. Abrisqueta b Consultant or advisory role: Janssen, Celgene, AbbVie, AstraZeneca Honoraria: Janssen, Celgene, AbbVie, AstraZeneca, Gilead Other remuneration: Speakers' bureau: Janssen, Celgene, AbbVie, AstraZeneca, Gilead B M. Andre b Research funding: Roche, Johnson & Johnson, Takeda Educational grants: Roche, Bristol-Myers-Squib, Celgene, Gilead, AbbVie, AstraZeneca Other remuneration: Advisory board: Takeda, Bristol-Myers-Squibb, Karyopharm, Gilead, Incyte. B Introduction: b Tafasitamab, an anti-CD19 immunotherapy that enhances antibody-dependent cellular cytotoxicity and phagocytosis, received accelerated approval in the USA and conditional authorization in Europe in combination with lenalidomide (LEN) for patients (pts) with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) ineligible for autologous stem cell transplant (ASCT) based on the results of the open-label, multicenter, single-arm, Phase II L-MIND study (NCT02399085; Salles G., et al. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text